Survodutide dosing (based on clinical trials) Survodutide is not yet commercially available, so dosing information comes from clinical trial protocols
This page provides research-only identity and documentation context, not cosmetic, dosing, clinical, therapeutic, veterinary, or human-use guidance
This remains an actively moving area, however: on February 27, 2026, the HHS Secretary publicly announced an intent to move roughly 14 of the 19 Category 2-listed peptides, reportedly including ipamorelin and CJC-1295, back toward Category 1 status, and multiple industry and legal-news outlets reported further FDA action in the following months easing Category 2-related restrictions on this group of peptides
[DOI] [Google Scholar] Shao HB, Chu LY, Lu ZH, Kang CM
Hawkins RA (2009) The blood-brain barrier and glutamate
Yue, S., Li, G., He, S